Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Evaluating Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer (MBC)

NCT07619365 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT07619365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07619365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Evaluating Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer (MBC)
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 31, 2031
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, metastatic breast cancer